

Mallinckrodt Documents – Annotated Bibliography

In addition to documents in the Archive, the following sources may be useful in understanding the context of the Mallinckrodt litigation.

Select Background Regarding General Opioid Litigation

- Minhee, C. (2021). [Opioid Settlement Tracker](#).

Tracks opioid-related litigation to determine whether settlements are being used to support public health efforts. Includes FAQs, timelines, and analysis.

- Bernstein, L., and Higham, S. (2017, Apr 2). [The Government's Struggle To Hold Opioid Manufacturers Accountable](#). *The Washington Post*.

Describes the Drug Enforcement Agency investigation into Mallinckrodt, targeting the problems of drug diversion in Florida. The government alleged that Mallinckrodt failed to meet its obligations to detect and report suspicious opioid orders, but the company settled the allegations for \$35 million.

Select Background Focused on Mallinckrodt

- Mallinckrodt Pharmaceuticals. (2021). [Our Story](#).

Narrates the history of Mallinckrodt, highlighting the company's innovations and range of products, from pharmaceutical drugs to photographic chemicals to the uranium oxide used by the Manhattan Project.

- Prime Clerk. (2021). [Mallinckrodt plc](#) (Case No. 20-12522).

Outlines the case background, important information and dates, parties, and debtors.

- Mallinckrodt Pharmaceuticals. (2022, Feb 3.). [Mallinckrodt Plan of Reorganization Confirmed by U.S. Court](#).

Shares updated terms of Mallinckrodt's opioid-related settlements. Quotes President and CEO Mark Trudeau saying that their reorganization plan will "reduce debt, address litigation claims and position the Company for long-term success."

- Brennan, J. (2021, Aug 3). [Mallinckrodt Faces Investor Revolt Over Opioid Crisis Handling](#). *The Irish Times*.

Examines the shareholder perspective of Mallinckrodt's bankruptcy reorganization, reporting that shareholder advisory firm Glass Lewis was advising shareholders to vote against some directors as a response to their handling of the opioid crisis.

- Breslin, J. (2021, Apr 8). [Epic Environmental Legal Battle, but Mallinckrodt, the St. Louis Company, Off the Hook](#). *St. Louis Record*.

Explains Mallinckrodt's affiliation with environmental litigation over mercury dumped in a river. Notes Mallinckrodt's merger and then separation with Covidien, and notes MNK's opioid-related legal challenges.

- Illinois Office of the Attorney General. (2020, Oct 15). [Attorney General Raoul Announces Updated Settlement with Opioid Manufacturer](#).

Details the terms of the October 2020 global settlement agreement with Mallinckrodt. Outlines the \$1.6 billion payment schedule and notes that Mallinckrodt agreed to terms guiding its opioid marketing and drug misuse systems.

- Mast, J. (2020, Oct 12). Drowning in litigation, [Mallinckrodt becomes third opioid producer to file for bankruptcy](#). *Endpoints News*.

Reports that Mallinckrodt filed for Chapter 11 bankruptcy, following Purdue Pharma and Insys Therapeutics, other major opioid producers. Notes Mallinckrodt's other legal challenges surrounding Medicaid rebates for multiple sclerosis drug Acthar Gel.

- Kaplan, S., and Hoffman, J. (2020, Feb 25.) [Mallinckrodt Reaches \\$1.6 Billion Deal to Settle Opioid Lawsuits](#). *The New York Times*.

Announces the tentative global settlement agreement, quoting Attorney General Xavier Becerra of California. Notes that Mallinckrodt is the first company to reach a tentative national settlement.